| Autor: |
Dang, Nam H., Fayad, Luis, McLaughlin, Peter, Romaguara, Jorge E., Hagemeister, Fredrick, Goy, Andre, Neelapu, Sattva, Samaniego, Felipe, Walker, Pamela L., Wang, Michael, Rodriguez, Maria A., Tong, Ann T., Pro, Barbara |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Aug2007, Vol. 138 Issue 4, p502-505, 4p, 2 Charts |
| Abstrakt: |
Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2–36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text